Share the tips below with your patients
Tips for the kitchen
Whether you're making a snack for yourself or preparing a feast for friends and family, these tips can help make your kitchen easier to use, even if you have low vision.
Create a System: Make sure all of your utensils, spices, and ingredients have their own place in the kitchen. Then make it a habit to put things away as soon as you are finished using them so they are easily found the next time. (You may need to ask family members to adopt your "system" so they don't put things back in the wrong place!)
Keep Cabinets Fully Closed or Fully Open: You can also try using contrasting tape (try white or black tape depending on the color of your cabinets) on the insides or backs of cabinet doors to make it easier to tell if one is open. Or install contrasting cabinet knobs or handles.
Perfect the Art of Touch: Tactile markings can help you tell the difference between similar types of containers. For example, wrap a rubber band around the juice container to tell it apart from the milk.
Sniff First, Sprinkle Second: There's nothing like mistaking pepper for cinnamon–so follow your nose when you're not sure!
Adopt the Art of Contrast: Use a cutting board that contrasts in color with the items you're slicing and dicing. Try to get a white cutting board and a black cutting board for your kitchen. So when you're cutting meat, use the white cutting board. Need to cut an onion? Use the black one. Also, use oven mitts, dishtowels, and utensils that contrast with your countertops to make them easier to find.
Measure Up: It can be tough to see the lines for each measure on a standard measuring cup. So try using divided measuring cups instead. They are generally easier to use. Even better: they are available in different colors, so you can adopt the color-contrast techniques described above.
Tips for lighting the home
Use consistent lighting: Reduce or eliminate shadows and bright spots by keeping light at a consistent brightness throughout your home. Light the night: Use night-lights to illuminate places like bathrooms, bedrooms, and hallways that you may use often during the evening hours.
Install cabinet lighting: Make using appliances easier by installing under-cabinet lights in your kitchen.
Maximize available light: When sitting to read, place available light directly over the shoulder on the same side of your body as the eye with the best vision.
IMPORTANT SAFETY INFORMATION AND INDICATIONS
LUCENTIS is contraindicated in patients with ocular or periocular infections or hypersensitivity to ranibizumab or any of the excipients in LUCENTIS.
WARNINGS AND PRECAUTIONS
Intravitreal injections, including those with LUCENTIS, have been associated with endophthalmitis and retinal detachment. Proper aseptic injection technique should always be utilized when administering LUCENTIS. Patients should be monitored following the injection to permit early treatment, should an infection occur.
Increases in intraocular pressure (IOP) have been noted both pre-injection and post-injection (at 60 minutes) with LUCENTIS. IOP and perfusion of the optic nerve head should be monitored and managed appropriately.
Although there was a low rate of arterial thromboembolic events (ATEs) observed in the LUCENTIS clinical trials, there is a potential risk of ATEs following intravitreal use of VEGF inhibitors. ATEs are defined as nonfatal stroke, nonfatal myocardial infarction, or vascular death (including deaths of unknown cause).
Neovascular (wet) age-related macular degeneration
The ATE rate in the 3 controlled neovascular AMD studies during the first year was 1.9% in the combined group of patients treated with 0.3 mg or 0.5 mg LUCENTIS compared with 1.1% in patients from the control arms. In the second year of Studies AMD-1 and AMD-2, the ATE rate was 2.6% in the combined group of LUCENTIS-treated patients compared with 2.9% in patients from the control arms. In Study AMD-4, the ATE rates observed in the study during the first year were similar to rates observed in Studies AMD- 1, AMD-2, and AMD-3.
In a pooled analysis of 2-year controlled studies (AMD-1, AMD-2, and a study of LUCENTIS used adjunctively with verteporfin photodynamic therapy), the stroke rate (including both ischemic and hemorrhagic stroke) was 2.7% in patients treated with 0.5 mg LUCENTIS compared to 1.1% in patients in the control arms (odds ratio 2.2 [95% confidence interval (0.8-7.1)]).
Macular edema following retinal vein occlusion
The ATE rate in the 2 controlled RVO studies during the first 6 months was 0.8% in both the LUCENTIS and control arms of the studies (4 of 525 in the combined group of patients treated with 0.3 mg or 0.5 mg LUCENTIS and 2 of 260 in the control arms). The stroke rate was 0.2% in the combined group of LUCENTIS-treated patients compared to 0.4% in the control arms.
Diabetic macular edema and Diabetic Retinopathy
In a pooled analysis of Studies DME-1 and DME-2, the ATE rate at 2 years was 7.2% with 0.5 mg LUCENTIS, 5.6% with 0.3 mg LUCENTIS, and 5.2% with control. The stroke rate at 2 years was 3.2% with 0.5 mg LUCENTIS, 1.2% with 0.3 mg LUCENTIS, and 1.6% with control. At 3 years, the ATE rate was 10.4% with 0.5 mg LUCENTIS and 10.8% with 0.3 mg LUCENTIS; the stroke rate was 4.8% with 0.5 mg LUCENTIS and 2.0% with 0.3 mg LUCENTIS.
Fatal events occurred more frequently in patients with DME and DR at baseline treated monthly with LUCENTIS compared with control. A pooled analysis of Studies DME-1 and DME-2 showed that fatalities in the first 2 years occurred in 4.4% of patients treated with 0.5 mg LUCENTIS, in 2.8% of patients treated with 0.3 mg LUCENTIS, and in 1.2% of control patients. Over 3 years, fatalities occurred in 6.4% of patients treated with 0.5 mg LUCENTIS and in 4.4% of patients treated with 0.3 mg LUCENTIS. Although the rate of fatal events was low and included causes of death typical of patients with advanced diabetic complications, a potential relationship between these events and intravitreal use of VEGF inhibitors cannot be excluded.
Serious adverse events related to the injection procedure that occurred in <0.1% of intravitreal injections included endophthalmitis, rhegmatogenous retinal detachment, and iatrogenic traumatic cataract.
In clinical trials in neovascular (wet) age-related macular degeneration, the most common ocular side effects included conjunctival hemorrhage, eye pain, vitreous floaters, increased IOP, vitreous detachment, and intraocular inflammation. The most common non-ocular side effects included nasopharyngitis, headache, arthralgia, and bronchitis.
In clinical trials in macular edema following retinal vein occlusion, the most common ocular side effects included conjunctival hemorrhage, eye pain, and maculopathy. The most common non-ocular side effects included nasopharyngitis, headache, influenza, and sinusitis.
In clinical trials in diabetic macular edema and diabetic retinopathy, the most common ocular side effects included conjunctival hemorrhage, cataract, increased IOP, and vitreous detachment. The most common non-ocular side effects included nasopharyngitis, anemia, and nausea.
As with all therapeutic proteins, there is the potential for an immune response in patients treated with LUCENTIS. The clinical significance of immunoreactivity to LUCENTIS is unclear at this time.
For additional safety information, please see LUCENTIS full prescribing information.
LUCENTIS® (ranibizumab injection) is indicated for the treatment of patients with:
- Neovascular (wet) age-related macular degeneration (wAMD)
- Macular edema following retinal vein occlusion (RVO)
- Diabetic macular edema (DME)
- Diabetic Retinopathy (Non Proliferative Diabetic Retinopathy (NPDR)), Proliferative Diabetic Retinopathy (PDR) in patients with Diabetic Macular Edema (DME)